GT Medical Technologies Completes $100 Million Series E to Advance GammaTile in Operable Brain Tumors

GT Medical Technologies has completed an oversubscribed $100 million Series E equity financing led by Viking Global Investors, with participation from existing investors MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures.

The funding will accelerate commercial and operational initiatives for GammaTile, the company's FDA‑cleared bioresorbable radiotherapy implant used for operable brain tumors, following the final data release from the ROADS randomized controlled trial in patients with newly diagnosed brain metastases.

Proceeds will also support continued expansion of the BRIDGES randomized controlled trial in patients with newly diagnosed glioblastomas (GBMs), reinforcing the company’s goal of making GammaTile a standard treatment for operable brain tumors.